Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials
Company Announcements

Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials

Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) just unveiled an update.

Shuttle Pharmaceuticals Holdings has finalized agreements with six cancer centers to conduct a Phase 2 clinical trial of its lead candidate, Ropidoxuridine, for treating glioblastoma, a deadly brain cancer. This trial aims to determine the optimal dosage for enhancing the effectiveness of radiation therapy. The company seeks to improve cancer cure rates and quality of life, with the trial expected to conclude in 18 to 24 months. This development presents a significant opportunity in the radiation therapy market.

See more insights into SHPH stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskShuttle Pharma Raises $4.5M for Clinical Trials
Sheryl Sheth3 Penny Stocks to Watch Now, 10/31/24
TheFlyShuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App